A Phase II "open", non-randomized multicenter Study to evaluate the Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Cancer of unknown Primary Origin and Progression or Recurrence after platinum-based Chemotherapy (CheCUP)

M. Pouyiourou, B. Kraft, T. Wohlfromm, M. Stahl, B. Kubuschok, H. Loeffler, U. Hacker, G. Huebner,C. B. Westphalen, M. Bitzer, T. Ernst, P. Schuett, T. Hielscher, S. Delorme, A. Stenzinger, T. Bochtler, A. Kraemer

ONCOLOGY RESEARCH AND TREATMENT（2022）

引用 0|浏览0